Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Ascendis Pharma A/S (Nasdaq: ASND) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The event will take place on Monday, January 13, 2025, at 11:15 a.m. Eastern Time / 8:15 a.m. Pacific Time in San Francisco, California.
Company executives will be presenting at the conference, and interested parties can access a live webcast of the presentation through the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. The webcast recording will remain available for 30 days following the event.
Ascendis Pharma A/S (Nasdaq: ASND) ha annunciato la sua partecipazione alla 43ª Conferenza Annuale sulla Salute J.P. Morgan. L'evento si svolgerà lunedì 13 gennaio 2025, alle 11:15 ora orientale / 8:15 ora del Pacifico a San Francisco, California.
I dirigenti dell'azienda presenteranno alla conferenza, e le parti interessate possono accedere a un webcast dal vivo della presentazione attraverso la sezione Investitori & Notizie del sito web di Ascendis Pharma all'indirizzo investors.ascendispharma.com. La registrazione del webcast rimarrà disponibile per 30 giorni dopo l'evento.
Ascendis Pharma A/S (Nasdaq: ASND) ha anunciado su participación en la 43ª Conferencia Anual de Atención Médica J.P. Morgan. El evento tendrá lugar el lunes 13 de enero de 2025, a las 11:15 a.m. hora del Este / 8:15 a.m. hora del Pacífico en San Francisco, California.
Los ejecutivos de la compañía presentarán en la conferencia, y las partes interesadas pueden acceder a un webcast en vivo de la presentación a través de la sección de Inversores y Noticias del sitio web de Ascendis Pharma en investors.ascendispharma.com. La grabación del webcast estará disponible durante 30 días después del evento.
Ascendis Pharma A/S (Nasdaq: ASND)는 제43회 JP모건 헬스케어 콘퍼런스에 참가한다고 발표했습니다. 이 행사는 2025년 1월 13일 월요일 오전 11:15 동부 표준시 / 오전 8:15 태평양 표준시 샌프란시스코, 캘리포니아에서 열립니다.
회사의 경영진이 콘퍼런스에서 발표할 예정이며, 관심 있는 분들은 Ascendis Pharma 웹사이트의 투자자 및 뉴스 섹션을 통해 발표의 실시간 웹캐스트에 접속할 수 있습니다. 웹캐스트 녹화는 행사 후 30일 동안 제공됩니다.
Ascendis Pharma A/S (Nasdaq: ASND) a annoncé sa participation à la 43e Conférence Annuelle sur la Santé J.P. Morgan. L'événement aura lieu le lundi 13 janvier 2025, à 11h15 heure de l'Est / 8h15 heure du Pacifique à San Francisco, Californie.
Des dirigeants de l'entreprise présenteront à la conférence, et les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la section Investisseurs & Actualités du site Web d'Ascendis Pharma à l'adresse investors.ascendispharma.com. L'enregistrement du webinaire restera disponible pendant 30 jours après l'événement.
Ascendis Pharma A/S (Nasdaq: ASND) hat seine Teilnahme an der 43. Jahreskonferenz der J.P. Morgan Healthcare bekannt gegeben. Die Veranstaltung findet am Montag, den 13. Januar 2025 um 11:15 Uhr Eastern Time / 8:15 Uhr Pacific Time in San Francisco, Kalifornien, statt.
Unternehmensvertreter werden auf der Konferenz präsentieren, und interessierte Parteien können über den Bereich Investoren & Nachrichten auf der Webseite von Ascendis Pharma unter investors.ascendispharma.com auf einen Live-Webcast der Präsentation zugreifen. Die Aufzeichnung des Webcasts bleibt für 30 Tage nach der Veranstaltung verfügbar.
- None.
- None.
COPENHAGEN, Denmark, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 11:15 a.m. Eastern Time / 8:15 a.m. Pacific Time in San Francisco, California.
A live webcast of the presentation will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days.
About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of Patients, Science, and Passion, Ascendis uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ ability to apply its innovative TransCon technology platform to build a leading, fully integrated biopharma company, and (ii) Ascendis’ use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis’ products and product candidates; unforeseen safety or efficacy results in Ascendis’ development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis’ development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ prospectus supplement filed on September 20, 2024 and Ascendis’ current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 20-F filed with the SEC on February 7, 2024. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group. © January 2025 Ascendis Pharma A/S.
| Investor Contacts: | Media Contact: | |
| Scott Smith | Melinda Baker | |
| Ascendis Pharma | Ascendis Pharma | |
| ir@ascendispharma.com | +1 (650) 709-8875 | |
| media@ascendispharma.com | ||
| Patti Bank | ||
| ICR Healthcare | ||
| +1 (415) 513-1284 | ||
| patti.bank@icrhealthcare.com |
FAQ
When is Ascendis Pharma (ASND) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Ascendis Pharma's (ASND) J.P. Morgan Healthcare Conference presentation?
How long will Ascendis Pharma's (ASND) 2025 J.P. Morgan presentation webcast be available?
Where is the 2025 J.P. Morgan Healthcare Conference featuring Ascendis Pharma (ASND) being held?
